NFLD Northfield Laboratories Inc. (MM)

The law firm of Milberg Weiss Bershad & Schulman LLP announces that a class action lawsuit was filed yesterday on behalf of purchasers of the securities of Northfield Laboratories, Inc. ("Northfield" or the "Company") (Nasdaq: NFLD), between February 20, 2004 and February 21, 2006, inclusive (the "Class Period"), seeking to pursue remedies under the Securities Exchange Act of 1934 (the "Exchange Act"). The action is pending in the United States District Court for the Northern District of Illinois against defendants Northfield and its CEO, Steven A. Gould. A copy of the complaint filed in this action is available from the Court, or can be viewed on Milberg Weiss's website at: http://www.milbergweiss.com If you bought the securities of Northfield between February 20, 2004 and February 21, 2006, inclusive, and sustained damages, you may, no later than May 19, 2006, request that the Court appoint you as lead plaintiff. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as "lead plaintiff." Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Milberg Weiss Bershad & Schulman LLP, or other counsel of your choice, to serve as your counsel in this action. The Complaint alleges that Northfield's sole business is the development of PolyHeme, an oxygen-carrying blood substitute for the treatment of urgent life-threatening blood loss in trauma and resultant surgical settings. The complaint further alleges that, throughout the Class Period, defendants made numerous positive statements about PolyHeme, each of which was materially false and misleading because defendants failed to disclose the results of a clinical trial that closed in 2000. In that clinical trial, ten of 81 patients who received PolyHeme suffered a heart attack within seven days, and two of those died, whereas, in contrast, none of the 71 patients in the clinical trial who received real blood were found to have suffered a heart attack. The truth emerged on February 22, 2006 with the publication of an article in The Wall Street Journal titled "Amid Alarm Bells, A Blood Substitute Keeps Pumping." The market was stunned by the disclosure of the theretofore secret adverse data contained in the article and the market price of Northfield's common stock fell with the belated disclosures. On February 21, 2006, the day before the disclosure by The Wall Street Journal, Northfield's common stock closed at a price of $12.23 per share. On February 22, 2006, on extraordinary volume of more than 4.1 million shares, Northfield's common stock closed at a price of $11.64 per share. Milberg Weiss Bershad & Schulman LLP (http://www.milbergweiss.com) is a firm with over 120 lawyers with offices in New York City, Los Angeles, Boca Raton, Delaware and Washington, D.C. and is active in major litigations pending in federal and state courts throughout the United States. Milberg Weiss has taken a leading role in many important actions on behalf of defrauded investors, consumers, and others for nearly 40 years. Please contact the Milberg Weiss website for more information about the firm. If you wish to discuss this action with us, or have any questions concerning this notice or your rights and interests with regard to the case, please contact the following attorneys: -0- *T Steven G. Schulman Peter E. Seidman Andrei V. Rado One Pennsylvania Plaza, 49th fl. New York, NY, 10119-0165 Phone number: (800) 320-5081 Email: sfeerick@milbergweiss.com Website: http://www.milbergweiss.com *T